ARTICLE | Company News
TapImmune, U.S. Department of Defense, Mayo Clinic cancer news
October 5, 2015 7:00 AM UTC
DoD awarded Mayo a $13.3 million grant to conduct a Phase II trial of TPIV200 to treat triple-negative breast cancer (TNBC). TapImmune said Mayo would begin the trial in 1Q16. The company plans to begin separate Phase II trials of the vaccine in TNBC by year end and in ovarian cancer early next year. ...